β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2

• Main Authors: Haibo Cheng (Author), Xiaoyin Ge (Author), Shiqin Zhuo (Author), Yanan Gao (Author), Bo Zhu (Author), Junfeng Zhang (Author), Wenbin Shang (Author), Dakang Xu (Author), Weihong Ge (Author), Liyun Shi (Author)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2018-11-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

The inhibitors for EGF receptor tyrosine kinase (EGFR-TKIs) such as gefitinib have been used as a standard treatment for non-small cell lung cancer (NSCLC), but the increasingly occurrence of drug resistance, the associated adverse effects and the enrichment of cancer stem cells significantly impede...